Webinars
UpTempo Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic
Watch this webinar to find out how UpTempo Antibody addresses key challenges bringing antibody therapeutic programs to clinical trials.
View Now
White Papers
White Paper - Accelerating Timelines to Clinic-The Race to First-In-Human with GPEx® Lightning
In this article, find out how GPEx® cell line and pools can accelerate the timelines to First-in-human studies.
View Now
Poster
Poster - GPEx® Lightning: Digital Control of Expression for Rapid, High-Titer Production of Complex Products in CHO Cells
A poster presentation of how Catalent's GPEx® Lightning system enables faster development timelines, robust manufacturing processes, improved titers, and higher final yields.
View Now
Webinars
Accelerate Your Cell Therapy to Clinic with a Flexible CGMP-Ready Process
This webinar explored the challenges of cell therapy manufacturing and introduced Catalent's UpTempo CAR-T Platform process as a solution.
View Now
Video
JPM Week 2024: Addressing the Latest Market Drivers and Trends for Biologics and Sterile Injectables
Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.
View Now
Poster
Poster: GMP Compliant iPSC Lines and Immune-Oncology Platform for Allogeneic Cell Therapy
A poster presentation of a GMP manufacturing process for the creation of human iPSC for use in allogeneic cell therapy applications.
View Now
Poster
Poster: Fully Closed, Scaled, Automated Analytics-on-Boarded GMP Compliant CAR-T Platform
A poster presentation of the UpTempo CAR-T Manufacturing Platform.
View Now
Executive Summary
Executive Summary - Process Optimization for Monoclonal Antibody (mAb) Commercial Manufacturing
Learn how Catalent took to a monoclonal antibody (mAb) from clinical to commercial phase under a highly compressed timeline.
View Now
Article
The Unique Challenges of Lipid Nanoparticle Development and Manufacturing
The use of lipid nanoparticles (LNPs) as non-viral delivery tools for messenger RNA (mRNA) helps alleviate the otherwise poor pharmacokinetics (PK) and in vivo instability of mRNA. However, LNP formulation development and manufacturing remains complex and challenging.
View Now
Article
Article: mRNA Development & Manufacturing: CMC Challenges & Solutions
The demand for mRNA-based vaccines and treatments has increased significantly, and the industry has been challenged to not only meet these needs, but also improve existing manufacturing processes and efficiencies.
View Now